A Novel PET Probe for Use in Cancer DiagnosisPoP: 09/19/2014 to 09/18/2016

用于癌症诊断的新型 PET 探针PoP：09/19/2014 至 09/18/2016

• 批准号: 8937517
• 负责人: MELISSA MOORE
• 金额: $ 149.28万
• 依托单位: SOFIE BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-19 至 2016-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8937517
• 关键词: Basic Science; Biological Assay; Biological Process; Cell Culture Techniques; Clinical; Clinical Trials; Computer software; Cyclic GMP; Diagnostic; Family; Image; Imaging technology; Investigation; Licensing; Malignant Neoplasms; Measures; Mus; Patients; Phosphorylation; Positron-Emission Tomography; Process; Prodrugs; Production; Radiolabeled; Research Personnel; Site; System; Tissues; cGMP production; commercialization; design; enzyme activity; imaging modality; molecular imaging; nano; novel; nucleoside analog; pre-clinical; radiotracer; response; tumor

PET is a molecular imaging modality that utilizes trace amounts of radiolabeled molecules ("probes") to target, measure, and image biological processes in tissue concentrations down to the range of nano-to picomoles. Imaging technologies from SOFIE and other companies allow the same probes to be used in cell cultures, mice, and patients to integrate findings from each of these settings with other basic science and clinical results. UCLA investigators developed, and licensed to SOFIE for further commercialization, a family of nucleoside analog probes, [18F]FAC, that are transported and trapped intracellularly by dCK phosphorylation. SOFIE and others can now reference UCLA INDs for these probes, allowing further investigation into [18F]FAC as diagnostic agents for assaying dCK enzyme activity in predicting tumor responses to dCK-dependent prodrugs. The main roadblock to widespread use of this probe is that currently, no commercial radiosynthesizer exists for synthesizing [18F]FAC for preclinical and clinical investigations. This proposal will develop a commercial, cGMP-compliant, automated radiosynthesizer and post-processing module to produce [18F]FAC.

PET是一种分子成像方式，它利用痕量的放射性标记分子（“探针”）将组织浓度的靶，测量和图像生物学过程降低到纳米到丘陵的范围。 Sofie和其他公司的成像技术允许在细胞培养物，小鼠和患者中使用相同的探针将这些环境中的每一种发现与其他基础科学和临床结果相结合。 加州大学洛杉矶分校的研究者开发并获得了Sofie的许可，以进行进一步的商业化，这是一个核苷模拟探针家族[18F] FAC，它们被DCK磷酸化在细胞内运输和捕获。索菲和其他人现在可以将UCLA IND引用这些探针，从而进一步研究[18F] FAC，作为测定DCK酶活性的诊断剂，以预测肿瘤对DCK依赖性前药的反应。 广泛使用该探针的主要障碍是，目前尚无用于合成[18F] FAC进行临床前和临床研究的商业放射合成器。该提案将开发出一个商业，符合CGMP的，自动的放射合成器和生产[18F] FAC的后加工模块。